Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Awake-101
- Development stage
- Preclinical
- Lead developer
- Matter Bio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Awake-101 is an investigational microbial-based immunotherapy developed by Matter Bio for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The therapy utilizes an attenuated strain of *Listeria monocytogenes* (LM) as a delivery vector for a tetanus toxoid (TT) recall antigen. The mechanism of action involves the bacteria selectively localizing and replicating within the immunosuppressive environment of the tumor and its metastases, where they are phagocytosed by tumor-associated macrophages and myeloid-derived suppressor cells. Once inside these cells, the *Listeria* secretes a fusion protein consisting of listeriolysin O (LLO) and the tetanus antigen. This process facilitates the recruitment and activation of pre-existing tetanus-specific memory T cells—originally generated through prior childhood vaccinations—to recognize and eliminate tumor cells. By converting the 'cold' tumor microenvironment into an immunologically 'hot' one, Awake-101 aims to provide a potent and targeted immune response against pancreatic cancer.
- Other names
- LM-LLO-TT
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on Awake-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Awake-101.